Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ABT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Dimensional Fund Advisors LP raised its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 12.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,188,864 shares of the medical research company's stock after buying an additional 239,313 shares
ArrowMark Colorado Holdings LLC boosted its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 23.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 597,931 shares of the medical research company's stock after purchasing an additional 113,603 shares during the
Bridgefront Capital LLC bought a new position in Exact Sciences Corporation (NASDAQ: EXAS) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,994 shares of the medical research company's stock, valued at approximately $656,000. Several other institutional investors have also recently made changes to their
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.
Banque Pictet & Cie SA decreased its stake in Exact Sciences Corporation (NASDAQ:EXAS – Free Report) by 77.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,415 shares of the medical research company’s stock after selling 151,772 shares during the quarter. Banque Pictet & Cie SA’s holdings in Exact Sciences were worth $4,612,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Ameriprise Financial Inc. grew its stake in shares of Exact Sciences by 105.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company’s stock valued at $245,802,000 after acquiring an additional 2,310,139 shares during the period. ARK Investment Management LLC raised its stake in Exact Sciences by 6,072,588.9% during the 3rd quarter. ARK Investment Management LLC now owns 2,186,168 shares of the medical research company’s stock worth $119,605,000 after acquiring an additional 2,186,132 shares during the period. Holocene Advisors LP lifted its holdings in Exact Sciences by 189.5% during the second quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock valued at $113,995,000 after purchasing an additional 1,404,086 shares in the last quarter. Amova Asset Management Americas Inc. lifted its holdings in Exact Sciences by 671.5% during the third quarter. Amova Asset Management Americas Inc. now owns 1,286,595 shares of the medical research company’s stock valued at $70,390,000 after purchasing an additional 1,119,830 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Exact Sciences by 643.1% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock worth $70,390,000 after purchasing an additional 1,113,459 shares during the period. Institutional investors own 88.82% of the company’s stock.
Exact Sciences Price Performance NASDAQ:EXAS opened at $104.91 on Friday. The business’s 50-day moving average is $103.52 and its 200 day moving average is $88.83. Exact Sciences Corporation has a 12 month low of $38.81 and a 12 month high of $104.98. The company has a market capitalization of $20.03 billion, a P/E ratio of -95.37, a P/E/G ratio of 2.02 and a beta of 1.41. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last released its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.29). The firm had revenue of $878.38 million for the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The business’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.06) EPS. On average, equities research analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades EXAS has been the topic of several recent analyst reports. BTIG Research restated a “neutral” rating on shares of Exact Sciences in a research report on Tuesday, March 24th. Evercore set a $105.00 target price on shares of Exact Sciences and gave the stock an “in-line” rating in a report on Monday, January 5th. Mizuho reiterated a “neutral” rating and issued a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Zacks Research cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Twenty-one investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $92.13.
View Our Latest Stock Analysis on EXAS
Exact Sciences Profile (Free Report)
Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.
Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.
Featured Articles Five stocks we like better than Exact Sciences Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS – Free Report).
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBanque Pictet & Cie SA Raises Stock Holdings in DexCom, Inc. $DXCM
NEXT HEADLINE »Banque Pictet & Cie SA Sells 26,340 Shares of Amrize Ltd $AMRZ
FNY Investment Advisers LLC acquired a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,500 shares of the medical research company’s stock, valued at approximately $2,894,000. Exact Sciences accounts for about 0.8% of FNY Investment Advisers LLC’s investment portfolio, making the stock its 23rd largest holding.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Earned Wealth Advisors LLC acquired a new position in Exact Sciences during the 4th quarter worth approximately $327,000. Legacy Capital Wealth Partners LLC bought a new stake in shares of Exact Sciences in the 4th quarter valued at about $42,000. Nisa Investment Advisors LLC lifted its position in shares of Exact Sciences by 50.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 34,188 shares of the medical research company’s stock valued at $3,472,000 after buying an additional 11,398 shares during the last quarter. Meyer Handelman Co. bought a new position in Exact Sciences during the fourth quarter worth $239,000. Finally, Birch Financial Group LLC bought a new stake in shares of Exact Sciences during the 4th quarter worth about $270,000. 88.82% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets Several brokerages have weighed in on EXAS. Zacks Research cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Evercore set a $105.00 target price on shares of Exact Sciences and gave the stock an “in-line” rating in a report on Monday, January 5th. Mizuho reaffirmed a “neutral” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a report on Tuesday, January 20th. BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research note on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Twenty-one research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Exact Sciences has an average rating of “Reduce” and an average target price of $92.13.
Get Our Latest Analysis on EXAS
Exact Sciences Price Performance Exact Sciences stock opened at $104.91 on Friday. The firm has a market capitalization of $20.03 billion, a price-to-earnings ratio of -95.37, a price-to-earnings-growth ratio of 2.02 and a beta of 1.41. The firm’s fifty day moving average price is $103.52 and its two-hundred day moving average price is $88.83. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $104.98. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last posted its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). The business had revenue of $878.38 million during the quarter, compared to analyst estimates of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The company’s revenue was up 23.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.06) EPS. On average, equities research analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.
Exact Sciences Profile (Free Report)
Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.
Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.
See Also Five stocks we like better than Exact Sciences Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS – Free Report).
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBristol Myers Squibb Company $BMY Shares Sold by Compagnie Lombard Odier SCmA
NEXT HEADLINE »Procter & Gamble Company (The) $PG Stake Lowered by Formidable Asset Management LLC
Exchange Traded Concepts LLC cut its stake in Exact Sciences Corporation (NASDAQ:EXAS – Free Report) by 39.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,044 shares of the medical research company’s stock after selling 5,932 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Exact Sciences were worth $919,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Westside Investment Management Inc. lifted its position in Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after acquiring an additional 271 shares in the last quarter. Quent Capital LLC purchased a new stake in shares of Exact Sciences during the third quarter valued at approximately $48,000. Bollard Group LLC acquired a new position in shares of Exact Sciences during the third quarter worth $55,000. OFI Invest Asset Management boosted its stake in shares of Exact Sciences by 241.2% in the third quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 767 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Exact Sciences by 463.0% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 1,216 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.
Analyst Ratings Changes EXAS has been the subject of a number of analyst reports. BTIG Research reissued a “neutral” rating on shares of Exact Sciences in a research report on Tuesday, March 24th. Zacks Research cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Evercore set a $105.00 price objective on Exact Sciences and gave the company an “in-line” rating in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a report on Thursday, January 22nd. Finally, Mizuho reaffirmed a “neutral” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research report on Tuesday, January 20th. Twenty-one investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $92.13.
View Our Latest Research Report on EXAS
Exact Sciences Price Performance EXAS opened at $104.91 on Friday. The company has a 50-day moving average of $103.57 and a 200-day moving average of $89.19. The company has a market capitalization of $20.03 billion, a P/E ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $104.98. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). The company had revenue of $878.38 million for the quarter, compared to the consensus estimate of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The business’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.06) EPS. Equities analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.
Exact Sciences Company Profile (Free Report)
Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.
Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.
Featured Articles Five stocks we like better than Exact Sciences
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEExchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN
NEXT HEADLINE »Exchange Traded Concepts LLC Purchases 2,608 Shares of iShares MSCI USA Momentum Factor ETF $MTUM
Capricorn Fund Managers Ltd acquired a new stake in shares of Exact Sciences Corporation (NASDAQ:EXAS – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 96,685 shares of the medical research company’s stock, valued at approximately $9,819,000. Exact Sciences makes up about 2.4% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 9th biggest position. Capricorn Fund Managers Ltd owned approximately 0.05% of Exact Sciences at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in EXAS. Walkner Condon Financial Advisors LLC lifted its stake in shares of Exact Sciences by 16.5% in the 4th quarter. Walkner Condon Financial Advisors LLC now owns 11,217 shares of the medical research company’s stock valued at $1,139,000 after purchasing an additional 1,588 shares during the period. Sowell Financial Services LLC bought a new position in Exact Sciences in the fourth quarter worth $301,000. Park Capital Management LLC WI bought a new position in Exact Sciences in the fourth quarter worth $234,000. Signaturefd LLC lifted its position in Exact Sciences by 5.5% during the fourth quarter. Signaturefd LLC now owns 2,346 shares of the medical research company’s stock valued at $238,000 after buying an additional 123 shares during the period. Finally, eCIO Inc. purchased a new position in Exact Sciences during the fourth quarter valued at $340,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.
Analysts Set New Price Targets A number of analysts have recently weighed in on EXAS shares. BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research report on Tuesday, March 24th. Mizuho reissued a “neutral” rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Zacks Research cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Evercore set a $105.00 target price on shares of Exact Sciences and gave the company an “in-line” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Exact Sciences in a report on Thursday, January 22nd. Twenty-one analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Exact Sciences has an average rating of “Reduce” and a consensus price target of $92.13.
Check Out Our Latest Analysis on EXAS
Exact Sciences Price Performance EXAS opened at $104.91 on Monday. The firm has a market cap of $20.03 billion, a PE ratio of -95.37, a P/E/G ratio of 2.02 and a beta of 1.41. The stock has a 50-day moving average price of $103.57 and a 200-day moving average price of $89.70. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $104.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last announced its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). The firm had revenue of $878.38 million for the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The business’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same period last year, the company posted ($0.06) earnings per share. Sell-side analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.
About Exact Sciences (Free Report)
Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.
Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.
Further Reading Five stocks we like better than Exact Sciences
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECapricorn Fund Managers Ltd Acquires Shares of 100,000 BrightSpring Health Services, Inc. $BTSG
NEXT HEADLINE »Karooooo Ltd. $KARO is Capricorn Fund Managers Ltd’s 8th Largest Position
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition.
Investors weighed near-term earnings strength against dilution from the company’s roughly $23 billion acquisition of Exact Sciences.
The company reported first-quarter results for the period ended March 31, with sales rising 7.8% on a reported basis and 3.7% on a comparable basis. It said results slightly topped analyst expectations.
GAAP diluted earnings per share came in at $0.61, while adjusted diluted EPS was $1.15, up 6% and excluding specified items.
Abbott said the Exact Sciences acquisition, completed on March 23, establishes it as a leader in oncology diagnostics and expands its presence in a new high-growth segment, but will weigh on near-term earnings.
The company forecast 2026 adjusted diluted earnings per share of $5.38 to $5.58, compared with a prior outlook of $5.55 to $5.80, citing about $0.20 of dilution tied to the deal.
It also maintained expectations for full-year 2026 comparable sales growth of 6.5% to 7.5%.
Abbott had previously guided to steady growth entering the year, and reiterated confidence in its trajectory despite integration costs from the acquisition.
“Our first-quarter results were aligned with our expectations to start the year,” Chairman and CEO Robert Ford said. “The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year.”
